Ann: JHC agrees to full commercial rollout of HeraCARE, page-4

HeraMED CEO and Cofounder Mr. David Groberman said: “This is a truly significant milestone for HeraMED. I am delighted we have reached this agreement with JHC as it demonstrates that our strategy of delivering clinical validation of the HeraCARE platform, which led to a successful paid pilot, provided the correct foundation for broader commercial rollout of HeraCARE within the hospital. 2022 will be a transformative year for HeraMED as we work towards delivering similar deployments with other key partners.


About the Commercial Agreement with JHC The key terms of the agreement are as follows:
● The commercial agreement is a 12-month extension of the commercial terms agreed under the paid pilot.
● HMD and JHC will continue discussions to extend this agreement for an additional three years
● HeraMED will gradually supply JHC with licences and equipment at a pace of approximately 400 licences each quarter to support JHC’s requirements to offer the new connected maternity care model to their audience of pregnancies
● Total estimated HeraCARE licenses fee for year number one based on the accumulated licenses as described is approximately A$ 220,000